Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Acorda Therapeutics Inc. ACOR

Acorda Therapeutics Inc is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Acorda uses scientific, clinical, and commercial expertise in neurology as strategic points of access in additional nervous system markets, including stroke, Parkinson's disease, and epilepsy. The company does not operate separate lines of business with respect to any of its products or product candidates. All of its net product revenue is derived from the United States.


Recent & Breaking News (NDAQ:ACOR)

Acorda Announces Safety and Tolerability Data from First Clinical Trial of Remyelinating Antibody in Multiple Sclerosis

Business Wire February 2, 2015

VBL Therapeutics Announces Ron Cohen and Philip Serlin Nominated to Board of Directors

GlobeNewswire January 20, 2015

Acorda Provides Corporate Update at J.P. Morgan Healthcare Conference

Business Wire January 12, 2015

Acorda to Present at the 33rd Annual J.P. Morgan Healthcare Conference

Business Wire January 6, 2015

Acorda Announces Initiation of Phase 3 Clinical Trial for Dalfampridine in Post-Stroke Walking Deficits

Business Wire December 15, 2014

Acorda Announces Initiation of Phase 3 Trial of CVT-301 in Parkinson's Disease

Business Wire December 10, 2014

Acorda Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference

Business Wire December 2, 2014

Acorda Therapeutics to Present at the Jefferies 2014 Global Healthcare Conference

Business Wire November 14, 2014

Acorda Therapeutics to Present at the Stifel 2014 Healthcare Conference

Business Wire November 12, 2014

Acorda Therapeutics to Present at the Credit Suisse 2014 Healthcare Conference

Business Wire November 4, 2014

Acorda Therapeutics Reports Third Quarter 2014 Financial Results

Business Wire October 30, 2014

Acorda Therapeutics to Host Conference Call to Discuss Third Quarter 2014 Financial Results on October 30, 2014

Business Wire October 23, 2014

Acorda Therapeutics Completes Acquisition of Civitas Therapeutics

Business Wire October 22, 2014

Acorda Therapeutics to Acquire Civitas Therapeutics

Business Wire September 24, 2014

Acorda Therapeutics and HealthCore to Present Real World Health Economics and Outcomes Data on Multiple Sclerosis Therapy AMPYRA

Business Wire September 10, 2014

Acorda Therapeutics to Present at the Aegis Capital 2014 Healthcare and Technology Conference

Business Wire September 4, 2014

Acorda Therapeutics to Present at the Morgan Stanley Global Healthcare Conference

Business Wire September 2, 2014

Acorda Therapeutics to Present at the Baird 2014 Healthcare Conference

Business Wire August 27, 2014

Acorda Therapeutics Reports Second Quarter 2014 Financial Results

Business Wire July 31, 2014

The Federal Reserve Playing Analyst Damaging to Biotechnology Companies

Accesswire July 30, 2014